Does Rallies show 13F holders for SNDX?

Yes. Rallies tracks hedge fund and 13F ownership data for SNDX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is SNDX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SNDX. It does not provide personalized investment advice.

SNDX (Syndax Pharmaceuticals, Inc.) Stock Analysis - Hedge Fund Holdings

Syndax Pharmaceuticals, Inc. (SNDX) is a publicly traded Healthcare sector company. As of May 21, 2026, SNDX trades at $19.62 with a market cap of $1.72B and a P/E ratio of -6.10. SNDX moved +4.08% today. Year to date, SNDX is -0.45%; over the trailing twelve months it is +90.44%. Its 52-week range spans $8.58 to $25.59. Analyst consensus is strong buy with an average price target of $39.91. Rallies surfaces SNDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns SNDX stock?

Hedge funds tracked by Rallies that own SNDX include Orbimed Advisors, Panagora Asset, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Syndax Pharmaceuticals, Inc..

SNDX Key Metrics

Key financial metrics for SNDX
Metric	Value
Price	$19.62
Market Cap	$1.72B
P/E Ratio	-6.10
EPS	$-3.29
Dividend Yield	0.00%
52-Week High	$25.59
52-Week Low	$8.58
Volume	729
Avg Volume	0
Revenue (TTM)	$172.35M
Net Income	$-285.42M
Gross Margin	0.00%

Top Hedge Funds Holding SNDX

Orbimed Advisors holds 962.30K shares of SNDX, changed -50.02% as of Mar 31, 2026.
Panagora Asset holds 249.41K shares of SNDX, changed +99.37% as of Mar 31, 2026.
Farallon Capital holds 10.00K shares of SNDX, changed +0.00% as of Mar 31, 2026.

Latest SNDX News

Syndax Highlights 12 Revuforj Abstracts Accepted for EHA 2026 — May 12, 2026
Syndax Q1 Revenue $64.9M, 50% Transplant Rate Delays Maintenance Restarts — May 1, 2026
Syndax Q1 Revenue Soars 224% to $64.9M, Revuforj Hits $48.9M — Apr 30, 2026
Syndax’s Revuforj Q4 Revenue Jumps 38% to $44.2M, 1,050 Patients Treated — Feb 27, 2026
Syndax Posts $68.7M Q4, $172.4M FY25 Revenue; Revuforj Up 38%, Niktimvo Up 22% — Feb 26, 2026

Recent SNDX Insider Trades

Metzger Michael A sold 17.16K (~$360.82K) on Feb 9, 2026.
Goldan Keith A. sold 3.41K (~$71.71K) on Feb 9, 2026.
Metzger Michael A sold 7.41K (~$152.84K) on Feb 6, 2026.

SNDX Analyst Consensus

12 analysts cover SNDX: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.91.

Common questions about SNDX

Who owns SNDX stock?: Hedge funds tracked by Rallies that own SNDX include Orbimed Advisors, Panagora Asset, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Syndax Pharmaceuticals, Inc..
Does Rallies show 13F holders for SNDX?: Yes. Rallies tracks hedge fund and 13F ownership data for SNDX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is SNDX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SNDX. It does not provide personalized investment advice.